AOL Money & Finance

biotechnology stocks posts

Feed

Gilead (GILD): New potential in 4-in-1 HIV drug

"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.

The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.

"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.

Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug

Sangamo (SGMO): Progress in adult stem calls?

"Sangamo BioSciences (NASDAQ: SGMO) has again received significant scientific validation for its proprietary technology," says biotech expert John McCamant.

In The Medical Technology Stock Letter, he explains, ""Part of what has gotten investors so excited about stem cells was the concept that some day scientists would be able to create 'personalized' stem cell types for individual therapy. We believe that this is the break that was needed to realize the potential of stem cell therapy."

"Stem cells differ from other cell types in two fundamental ways. First, they are unspecialized cells capable of renewing themselves through cell division.

"Second, under certain conditions, they can be induced to become tissue- or organ-specific cells with special functions.

Continue reading Sangamo (SGMO): Progress in adult stem calls?

Gilead (GILD): 'A stock for all seasons'

"Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green.

The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects."

"Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.)

Continue reading Gilead (GILD): 'A stock for all seasons'

Celgene (CELG): Cancer progress boosts biotech

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Sinovac (SVA): Chinese biotech bet

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"One Chinese sector being relatively ignored by Wall Street is the biotech industry," notes Keith Fitz-Gerald. In The New China Trader, he looks to a biotech speculation -- Sinovac (AMEX: SVA).

"The government knows that the wheels could fall off the bike rather quickly if average Chinese citizens begin to see a dramatic reversal in their health and happiness.

Continue reading Sinovac (SVA): Chinese biotech bet

Illumina (ILMN): Genetic workhorse

"Illumina (NASDAQ: ILMN) makes the Genome Analyzer, which is the workhorse of the genetic medicine revolution," says growth expert Mike Cintolo in The Cabot Top Ten Report.

"The Illumina Genome Analyzer is used by genomic research centers, academic institutions, agriculture and livestock companies, pharmaceutical companies, clinical research organizations and biotechnology companies all over the world.

"In the fourth quarter of 2008, for example, the company launched the In? nium HD HumanCytoSNP-12 BeadChip, a 12 sample BeadChip priced as low as $125 per sample that enables researchers to analyze nearly 300,000 genetic markers per sample.

Continue reading Illumina (ILMN): Genetic workhorse

Diagnostics duo: Myriad (MYGN) and Thoratec (THOR)

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Continue reading Diagnostics duo: Myriad (MYGN) and Thoratec (THOR)

Don't be a sheep -- beware of biotech (VPHM)

As an investor, I hate crowds. If a stock or sector that I like attracts a crowd, I know it is time to leave. As they say, the sheep are usually the buyers at the top.

Now, we need sheep to help drive prices of our holdings higher, but at some point it is time to jettison. Nothing goes up forever, and the best signal I have found over the years is to sell when the sheep are buying.

This year the sheep are being told to buy the biotechnology sector.

That advice may be a bit late in coming. 2008 was a disastrous year, but biotechnology did very well. It is that performance that is now attracting the sheep.

Continue reading Don't be a sheep -- beware of biotech (VPHM)

Top Stock Picks '09: Biogen Idec (BIIB)

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Biogen Idec (NASDAQ: BIIB) -- which has a highly effective though risky treatment for multiple sclerosis called Tysabri -- is our top pick for 2009," says analyst Richard Moroney.

The editor of Dow Theory Forecasts, an advisory that has been published for more than 50 years, explains, "Despite superior growth prospects, the Tysabri concerns have kept Biogen's shares under pressure.

"In the past two months, consensus profit estimates have crept upwards for Biogen Idec. Per-share profits are expected to climb 33% in 2008 and 9% in 2009. Over the next five years, profits are expected to climb 12% annually. Two factors support this outlook.

"First, Biogen plows nearly a third of its revenue into research and development, raising expectations of a fertile lineup of new drugs. Second, there's Tysabri, a highly effective though risky treatment for multiple sclerosis.

Continue reading Top Stock Picks '09: Biogen Idec (BIIB)

Top Stock Picks '09: Emergent BioSolutions (EBS)

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Emergent BioSolutions (NYSE: EBS) -- my top 2009 pick -- makes the only FDA-licensed vaccine for the prevention of anthrax," says Timothy Lutts in his The Cabot Stock of the Month.

"Located in Rockville, Maryland, the company is currently filling a $448 million government order for 18.75 million doses, and in October, the U.S. government contracted to purchase 14.5 million additional doses valued at up to $404 million, to add to the Strategic National Stockpile.

"The vaccine is named BioThrax, and it accounts for 97% of the revenues of Emergent BioSolutions. However, the company has a full pipeline including two 'next generation' anthrax vaccines.

"Also in development are two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic (botulinum is the nasty form of Botox), an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy and a chlamydia vaccine.

Continue reading Top Stock Picks '09: Emergent BioSolutions (EBS)

Top Stock Picks '09: Myriad Genetics (MYGN)

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"My top idea for 2009 is Myriad Genetics (NASDAQ: MYGN)," says Mike Cintolo. In The Cabot Market Letter, he looks at "the leader in the new field of cancer predisposition testing."

"Myriad Genetics five tests on the market (covering colon, breast, ovarian, and skin cancer) that tell a patient if his genes make it more likely that he'll get various types of cancer.

"During the past few quarters, revenues from these tests have risen at a 50% annual clip, and there's no sign of that slowing down.

"The company also has a pharmaceutical division, but it's going to spin that off sometime in 2009. That should be a big positive, as the drug development division carries good potential, but also big-time costs. Once the cancer predisposition testing division is on its own, much of that revenue growth is going to fall to the bottom line.

Continue reading Top Stock Picks '09: Myriad Genetics (MYGN)

Bet on a biotech bull

"Bull markets have been few and far between this summer; one of the few sectors that looks to have re-entered a bull trend is biotechnology," says international investing expert Nick Vardy.

In his Global Bull Market Alert, he explains, "The S&P Biotech ETF (ASE: XBI) looks to capitalize on this traditionally highly volatile and boom bust burdened sector." Here's his bullish assessment.

"Why the sudden merger and acquisitions frenzy in biotech? Put simply, 'Big Pharma' is cash-rich but innovation-poor. As patents expire, the traditional pharmaceutical industry is eager to refill its emptying drug pipelines.

"On the one hand, Big Pharma hopes giant acquisitions jump start pharmaceuticals' sputtering innovation machines. On the other hand, existing biotech blockbusters would also hedge against the coming collapse in earnings from drugs that are coming off patent.

"So why buy biotech now? Technically, biotech is one of the few sectors in the market that are in an uptrend. And while the sector has sold off recently, we think it is a good time to get in.

"The best way to profit from the biotech bull is through the S&P Biotech ETF. Unlike some other market cap weighted biotech ETFs which heavily lean toward industry giants Genentech and Amgen, XBI holds about 25 of the top companies across the entire sector.

"Each company is equally weighted between 3-5% of the ETF. With an industry low expense ratio of 0.35%, it is also the bargain of the biotech ETF sector."

Steven Halpern's TheStockAdvisors.com offers a daily look at the latest market commentary and favorite stock picks and investment ideas from the nation's leading financial newsletter advisors.

Cepheid (CPHD): The next generation of diagnostics

"I still love Cepheid (NASDAQ: CPHD)," says biotechnology sector expert Michael Shulman in his ChangeWave Biotech Investor.

The advisor explains, "Cepheid does genetic testing of the things that can make us sick or kill us. The company is at the forefront of the next generation of diagnostics testing, and has real products already on the market." Here is his review.

"Cepheid has had outrageous sales success in the past few quarters and, therefore, has excellent profits looming. However, the true value for the company is its long-term potential.

"CPHD broke out about a year ago with a new test for the killer staph infection, MRSA, and the test is an order-of-magnitude better than any the competition has.

"A combination of tremendous public pressure and a CDC report that said MRSA kills at least 17,000 people per annum (and consumes billions of dollars, already), have hospitals everywhere putting in MRSA screening and prevention programs. And nine out of 10 of those hospitals are buying CPHD's equipment and tests.

Continue reading Cepheid (CPHD): The next generation of diagnostics

Invitrogen (IVGN): A 'split' candidate buy

Buying only stocks announcing splits, Neil Macneale has developed a leading long-term track record. His latest buy in his 2-for-1 newsletter is biotechnology research products firm Invitrogen (NASDAQ: IVGN).

"Wow, investing today is like riding a ping-pong ball; last month I was feeling quite glum about the market and cautioned that we were in for an extended period of below normal portfolio growth.

"That may still be true, but now, as we go to press, the portfolio is at its all-time high and there is reason to believe most stocks we have picked are going to do much better than the overall market.

"Meanwhile, with splits so few and far between these days, one thing is certain; companies that do announce splits deserve a very close look. Our latest selection is Invitrogen. Its primary business is assembling and selling kits used in biotech research.

"I view this as selling the shovels and tents to the gold miners. During the California gold rush, it was the storekeepers that got rich while most of the miners went broke.

"IVGN is not ideal in that it pays no dividend and carries a moderate amount of debt. However, this is a strong business with a history of good earnings and good growth. The healthcare sector has been on the outs for a while now and it's probably a good time to get a biotech company into the portfolio."

Each day, Steven Halpern's TheStockAdvisors.com offers the latest market commentary and favorite investment ideas from the nation's leading financial newsletter advisors.

The dumbing down of the global economy

A graph from the May 2008 issue of Harvard Business Review tells a story about the dumbing down of the global economy.

From an article, Rebuilding the R&D Engine in Big Pharma [subscription required] the graph shows the total shareholder returns for various industries in two time periods: from 1985 to 2000 and from 2001 to 2007. Here are three of the leading sectors from 1985 to 2000 (average annual shareholder returns are in parentheses):

  • Pharmaceuticals (20.0%)
  • Financials (18.8%)
  • IT (17.4%)

Between 2001 and 2007, three of the leading sectors were:

  • Energy (15.2%)
  • Materials (14.3%)
  • Financials (7.0%)

Continue reading The dumbing down of the global economy

Next Page >

Symbol Lookup
IndexesChangePrice
DJIA+172.4610,195.88
NASDAQ+34.422,146.86
S&P 500+19.791,089.09

Last updated: November 09, 2009: 02:17 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance